Free Smart Phone Healthcare Newsletter Want to receive the latest updates on smart phones, gadgets and technology for healthcare? Join thousands of healthcare pros who subscribe to Smart Phone HC for FREE!

Digital Health, Mobile Health, mHealth, etc Is Just Health?

Last week, the big news in the world of healthcare IT was that HIMSS acquired Health 2.0. You can check out the great writeup of the acquisition by Andy Oram. This acquisition was interesting since Health 2.0 had largely tried to be the anti-HIMSS for so long. There were others doing so as well like the mHealth Summitt and the Connected Health Conference, but those have all been acquired by HIMSS as well.

It’s no surprise that running a conference focused on startup companies doing innovative things in healthcare is a hard business. Startup companies have no money and so they can’t spend on oversized booths like the large vendors at HIMSS do. Indu and Matthew did what they could with Health 2.0, but it’s a challenging business. It will be interesting to see how things go under the HIMSS umbrella.

I know that Matthew Holt who started Health 2.0 has been beating the drum for a long time that there’s no such thing as mobile health or mHealth or Digital Health. There’s just healthcare. So, in some ways it makes sense for something like Health 2.0 to be part of a healthcare IT organization like HIMSS.

For the most part, I agree with Matthew on there not being a difference. However, I think that what this misses is that within the healthcare IT world there are companies at different stages of development. I divide these companies into 3 categories: Large Enterprise Companies, Middle Tier Companies, and Startup Companies. We could slice and dice some more, but I think this is a good framework for thinking about the industry.

Whether you liked the description of digital health or mobile health or mHealth, those terms came to represent what most people would consider startup healthcare IT companies. That’s what Health 2.0 and a few other conferences came to represent. Despite many efforts on their part to expand in other ways, HIMSS has largely come to represent the large enterprise companies. They’ve done so in a really fantastic way, but these large enterprise companies kind of suck the wind out of events like the HIMSS Annual conference.

What’s interesting to me is that the middle tier healthcare IT companies haven’t really had a place to go. Sure, they might go to HIMSS, but they generally do smaller booths and they go to show they’re a player in the space versus going to attract customers and do business deals. Same goes for Health 2.0. They might attend Health 2.0 to see what’s happening in the market, but it’s not a great event for their businesses generally either.

Along those same lines, I think that most middle tier hospitals and healthcare organizations get left out as well. They’re too small to be able to be the pilot site for a startup company and they get lost at an event like HIMSS. These middle tier healthcare organizations are interesting because they have money to spend if they can find something that works. However, they don’t have the bandwidth to be someone’s innovation center for something that might work.

No doubt, digital health is just becoming part of the overall healthcare system. However, the division between size of companies and the maturity of their products is not going to change. Not to mention the needs of the various sized healthcare organizations. It will be interesting to see what happens to Health 2.0 under HIMSS and how the market continues to evolve to better serve its stakeholders.

April 26, 2017 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 10 blogs containing over 8000 articles with John having written over 4000 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 16 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.

MindCrowd Memory Test

This week I was the moderator at the DellEMC #TranformHIT Healthcare Think Tank event. It was a great event and if you missed it, you can search the #TranformHIT on Twitter or find the recording in the embedded video at the bottom of this post.

One of the highlights of the event for me was meeting Dr. Jeff Trent From TGen, a nonprofit institute focused on translating genomic research into life-changing results. The work they’re doing is really quite incredible and Dr. Trent offered some great insights at the Think Tank.

One of the research projects at TGen is called Mind Crowd. This research looks at memory and other brain related diseases. As part of the study, they’re trying to get 1 million people to participate in a fun, but simple mind test on their site. The test takes about 10 minutes, but try it out and see how you do.

What’s fascinating about the results they’ve already seen from the 74k+ people who have taken the test to date is that women of all ages actually have better memory than men. There are outliers, but across the data it’s very clear that in this test women remember things better than men.

To add to these findings, there’s also an interesting thing that happens when women approach the age of menopause. Women at that age seem to actually get an increase in their memory. It’s not clear why this is the case, but the data shows an uptick in memory about the time most women hit menopause.

Tgen is also taking the outliers and working with them to study why their memory is so much better or worse (ie. an older person with an incredible memory or a younger person with a poor memory). I’m interested to see what comes from these studies.

If you want to contribute to their research, take 10 minutes and go and participate in their Mind Test.
Read more..

April 19, 2017 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 10 blogs containing over 8000 articles with John having written over 4000 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 16 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.

23andMe Gets FDA Authorization for Consumer Genetic Health Risk Reports

The big news about 23andMe’s FDA approval came out last week when I was holed up at a conference.

That’s right. 23andMe can now directly offer consumers a genetic health risk report that’s FDA approved. This is a big step for 23andMe when you consider that they’d previously gotten their hand slapped by the FDA.

23andMe got what’s called a de novo authorization from the FDA. This is something we’re likely to see more of and something that I’m sure many people aren’t familiar with. Here’s a description of what a de novo authorization is from the 23andMe announcement:

What does it mean to be granted a de novo authorization?
The Food and Drug Administration Modernization Act of 1997 (FDAMA) added the de novo classification option, which provides an alternate pathway to classify novel devices of low to moderate risk. The de novo process is used by the FDA to grant marketing authorization for devices that are new and unlike any other on the market. In addition de novo marketing authorization means that 23andMe met the FDA’s premarket requirements to demonstrate the following: accuracy, validity and user comprehension.

I’m glad that the FDA has created this new form of authorization for companies like 23andMe. This story also stands in stark contrast to other FDA related stories like Theranos. I’m sure that 23andMe would hate the comparison. However, there are some similarities. They both got slapped by the FDA. However, their response to the FDA’s notices was completely different. That’s why 23andMe seems to still be thriving and now have FDA approval. Theranos is floundering with reports that their founder now owes the company $25 million.

Needless to say, if you’re a healthcare startup, make sure you know the FDA regulations that apply to your startup.

April 11, 2017 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 10 blogs containing over 8000 articles with John having written over 4000 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 16 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.